BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012;82:116-40. [DOI: 10.1016/j.critrevonc.2011.05.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Yegin EG, Siykhymbayev A, Eren F, Bekiroglu N, Ozdogan OC. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Annals of Hepatology 2013;12:915-25. [DOI: 10.1016/s1665-2681(19)31297-9] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Zhong D, Cen H. Aberrant promoter methylation profiles and association with survival in patients with hepatocellular carcinoma. Onco Targets Ther 2017;10:2501-9. [PMID: 28507442 DOI: 10.2147/OTT.S128058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
3 Lyytinen I, Lempinen M, Nordin A, Mäkisalo H, Stenman UH, Isoniemi H. Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma. Scand J Gastroenterol 2013;48:1066-73. [PMID: 23889187 DOI: 10.3109/00365521.2013.805810] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
4 Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;1:593-598. [PMID: 24649215 DOI: 10.3892/mco.2013.119] [Cited by in Crossref: 135] [Cited by in F6Publishing: 130] [Article Influence: 15.0] [Reference Citation Analysis]
5 Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH, Kim JK, Wang HJ, Cheong JY, Cho SW. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment. Cytokine. 2015;73:245-252. [PMID: 25797190 DOI: 10.1016/j.cyto.2015.02.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
6 Hasanzad M, Sarhangi N, Aghaei Meybodi HR, Nikfar S, Khatami F, Larijani B. Precision Medicine in Non Communicable Diseases. Int J Mol Cell Med 2019;8:1-18. [PMID: 32351905 DOI: 10.22088/IJMCM.BUMS.8.2.1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Zhang W, Kim R, Quintini C, Hashimoto K, Fujiki M, Diago T, Eghtesad B, Miller C, Fung J, Tan A. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation. Liver Transpl. 2015;21:101-111. [PMID: 25283528 DOI: 10.1002/lt.24013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
8 Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Mastroiaco V, Vetuschi A, Sferra R, Barnabei R, Capece D, Zazzeroni F, Alesse E. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. BMC Cancer 2016;16:3. [PMID: 26728044 DOI: 10.1186/s12885-015-2007-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 8.5] [Reference Citation Analysis]
9 Zhang L, Chen J, Gao C, Liu C, Xu K. An efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programming. Med Biol Eng Comput 2018;56:1771-9. [DOI: 10.1007/s11517-018-1811-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Liu F, Pan Z, Zhang J, Ni J, Wang C, Wang Z, Gu F, Dong W, Zhou W, Liu H. Overexpression of RHEB is associated with metastasis and poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:3838-45. [PMID: 29467900 DOI: 10.3892/ol.2018.7759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Lee WC. Value of alpha-fetoprotein in hepatocellular carcinoma. Transl Gastroenterol Hepatol 2021;6:52. [PMID: 34805574 DOI: 10.21037/tgh.2019.12.19] [Reference Citation Analysis]
12 Kozlowska J, Mikula T, Suchacz M, Jabnonska J, Stanczak W, Cianciara J, Wiercinska-Drapalo A. Pigment epithelium-derived factor and matrix metalloproteinase-9 in liver cirrhosis. Saudi J Gastroenterol 2016;22:375-9. [PMID: 27748324 DOI: 10.4103/1319-3767.191143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Cho HJ, Kim SS, Nam JS, Kim JK, Lee JH, Kim B, Wang HJ, Kim BW, Lee JD, Kang DY, Kim JH, Jae YM, Hwang JC, Shin SJ, Lee KM, Cho SW, Cheong JY. Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients with hepatocellular carcinoma who underwent curative treatment. Clin Res Hepatol Gastroenterol. 2017;41:181-189. [PMID: 27839726 DOI: 10.1016/j.clinre.2016.09.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
14 Taniai T, Shirai Y, Shiba H, Sakamoto T, Furukawa K, Yanaga K. Spontaneous Pathological Complete Regression of Hepatocellular Carcinoma. Case Rep Gastroenterol 2018;12:653-9. [PMID: 30519151 DOI: 10.1159/000494551] [Reference Citation Analysis]
15 Burkhart RA, Ronnekleiv-Kelly SM, Pawlik TM. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg Oncol. 2017;26:138-145. [PMID: 28577719 DOI: 10.1016/j.suronc.2017.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
16 Aglan HA, Ahmed HH, El-Toumy SA, Mahmoud NS. Gallic acid against hepatocellular carcinoma: An integrated scheme of the potential mechanisms of action from in vivo study. Tumour Biol 2017;39:1010428317699127. [PMID: 28618930 DOI: 10.1177/1010428317699127] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
17 Wang J, Zuo Y, Man YG, Avital I, Stojadinovic A, Liu M, Yang X, Varghese RS, Tadesse MG, Ressom HW. Pathway and network approaches for identification of cancer signature markers from omics data. J Cancer 2015;6:54-65. [PMID: 25553089 DOI: 10.7150/jca.10631] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
18 Zhu Z, Li L, Xu J, Ye W, Chen B, Zeng J, Huang Z. Comprehensive analysis reveals a metabolic ten-gene signature in hepatocellular carcinoma. PeerJ 2020;8:e9201. [PMID: 32518728 DOI: 10.7717/peerj.9201] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
19 Perumal S, Langeshwaran K, Selvaraj J, Ponnulakshmi R, Shyamaladevi B, Balasubramanian MP. Effect of diosmin on apoptotic signaling molecules in N-nitrosodiethylamine-induced hepatocellular carcinoma in experimental rats. Mol Cell Biochem 2018;449:27-37. [PMID: 29479636 DOI: 10.1007/s11010-018-3339-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
20 Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. Cancer Metastasis Rev. 2013;32:229-268. [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
21 Zhu GQ, Yang Y, Chen EB, Wang B, Xiao K, Shi SM, Zhou ZJ, Zhou SL, Wang Z, Shi YH, Fan J, Zhou J, Liu TS, Dai Z. Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. J Transl Med 2019;17:203. [PMID: 31215439 DOI: 10.1186/s12967-019-1946-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
22 Waidely E, Al-Yuobi AR, Bashammakh AS, El-Shahawi MS, Leblanc RM. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst. 2016;141:36-44. [PMID: 26606739 DOI: 10.1039/c5an01884f] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
23 Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. European Journal of Cancer 2012;48:1977-87. [DOI: 10.1016/j.ejca.2012.01.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
24 Fu YP, Yi Y, Huang JL, Jing CY, Sun J, Ni XC, Lu ZF, Cao Y, Zhou J, Fan J, Qiu SJ. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. Oncologist 2017;22:561-9. [PMID: 28438885 DOI: 10.1634/theoncologist.2016-0231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
25 Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465. [PMID: 24745023 DOI: 10.1155/2014/741465] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
26 Ceborska M, Szwed K, Suwinska K. β-Cyclodextrin as the suitable molecular container for isopulegol enantiomers. Carbohydr Polym 2013;97:546-50. [PMID: 23911483 DOI: 10.1016/j.carbpol.2013.04.097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
27 Li B, Feng W, Luo O, Xu T, Cao Y, Wu H, Yu D, Ding Y. Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma. Sci Rep 2017;7:5517. [PMID: 28717245 DOI: 10.1038/s41598-017-04811-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
28 Tian Y, Luo Y, Wang J. MicroRNA-425 induces apoptosis and suppresses migration and invasion of human cervical cancer cells by targeting RAB2B. Int J Immunopathol Pharmacol 2021;35:20587384211016131. [PMID: 34024178 DOI: 10.1177/20587384211016131] [Reference Citation Analysis]
29 Ahmed HH, Shousha WG, Shalby AB, El-mezayen HA, Ismaiel NN, Mahmoud NS. Curcumin: a unique antioxidant offers a multimechanistic approach for management of hepatocellular carcinoma in rat model. Tumor Biol 2015;36:1667-78. [DOI: 10.1007/s13277-014-2767-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
30 Chen R, Li J, Zhou X, Liu J, Huang G. Fructose-1,6-Bisphosphatase 1 Reduces 18F FDG Uptake in Hepatocellular Carcinoma. Radiology 2017;284:844-53. [PMID: 28387640 DOI: 10.1148/radiol.2017161607] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
31 Valencia-Quintana R, Sánchez-Alarcón J, Tenorio-Arvide MG, Deng Y, Montiel-González JM, Gómez-Arroyo S, Villalobos-Pietrini R, Cortés-Eslava J, Flores-Márquez AR, Arenas-Huertero F. The microRNAs as potential biomarkers for predicting the onset of aflatoxin exposure in human beings: a review. Front Microbiol 2014;5:102. [PMID: 24672518 DOI: 10.3389/fmicb.2014.00102] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
32 Zhang S, Xiao Q, Shi Z, Yu G, Ma XP, Chen H, Zhang P, Shen S, Sai-Yin HG, Chen TY, Lu PX, Wang NJ, Ren W, Huang P, Xie J, Conran C, Zheng SL, Yu L, Xu J, Jiang DK. Caspase polymorphisms and prognosis of hepatocellular carcinoma. PLoS One 2017;12:e0176802. [PMID: 28453560 DOI: 10.1371/journal.pone.0176802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
33 Lempinen M, Lyytinen I, Nordin A, Tervahartiala T, Mäkisalo H, Sorsa T, Isoniemi H. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma. Ann Med 2013;45:482-7. [PMID: 23962148 DOI: 10.3109/07853890.2013.823779] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
34 Xia W, Chen Y, Zhang R, Yan Z, Zhou X, Zhang B, Gao X. Radiogenomics of hepatocellular carcinoma: multiregion analysis-based identification of prognostic imaging biomarkers by integrating gene data-a preliminary study. Phys Med Biol. 2018;63:035044. [PMID: 29311419 DOI: 10.1088/1361-6560/aaa609] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
35 Paolino G, Corsetti P, Moliterni E, Corsetti S, Didona D, Albanesi M, Mattozzi C, Lido P, Calvieri S. Mast cells and cancer. G Ital Dermatol Venereol 2019;154:650-68. [PMID: 29192477 DOI: 10.23736/S0392-0488.17.05818-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 Wan XX, Chen HC, Khan MA, Xu AH, Yang FL, Zhang YY, Zhang DZ. ISG15 inhibits IFN-α-resistant liver cancer cell growth. Biomed Res Int 2013;2013:570909. [PMID: 24024201 DOI: 10.1155/2013/570909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
37 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 256] [Article Influence: 69.7] [Reference Citation Analysis]
38 Mathew S, Ali A, Abdel-hafiz H, Fatima K, Suhail M, Archunan G, Begum N, Jahangir S, Ilyas M, Chaudhary AG, Al Qahtani M, Mohamad Bazarah S, Qadri I. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infection, Genetics and Evolution 2014;26:327-39. [DOI: 10.1016/j.meegid.2014.06.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
39 Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
40 Zhao NH, Qian Y, Wu CS, Wang JW, Fang Y, Fan XP, Gao S, Fan YC, Wang K. Diagnostic value of NKG2D promoter methylation in hepatitis B virus-associated hepatocellular carcinoma. Biomark Med 2019;13:1093-105. [PMID: 31411040 DOI: 10.2217/bmm-2019-0102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Cheng M, Xiong E, Tian T, Zhu D, Ju HQ, Zhou X. A CRISPR-driven colorimetric code platform for highly accurate telomerase activity assay. Biosens Bioelectron 2021;172:112749. [PMID: 33160233 DOI: 10.1016/j.bios.2020.112749] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
42 Yin F, Shu L, Liu X, Li T, Peng T, Nan Y, Li S, Zeng X, Qiu X. Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res 2016;35:127. [PMID: 27567667 DOI: 10.1186/s13046-016-0403-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
43 Asham EH, Kaseb A, Ghobrial RM. Management of Hepatocellular Carcinoma. Surgical Clinics of North America 2013;93:1423-50. [DOI: 10.1016/j.suc.2013.08.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
44 Zhao Y, Gao Q, Pei L, Wang C, Jin L, Liao F. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. Int J Biol Markers 2017;32:361-9. [DOI: 10.5301/ijbm.5000299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
45 Tian MM, Fan YC, Zhao J, Gao S, Zhao ZH, Chen LY, Wang K. Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B. Clin Res Hepatol Gastroenterol 2017;41:171-80. [PMID: 28189396 DOI: 10.1016/j.clinre.2016.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]